trending Market Intelligence /marketintelligence/en/news-insights/trending/id_lfps7acexjvttkhuzxg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Sun Pharmaceutical skin drug bags US FDA approval

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Sun Pharmaceutical skin drug bags US FDA approval

India's Sun Pharmaceutical Industries Ltd. secured the U.S. Food and Drug Administration's approval to market Ilumya as a treatment for moderate-to-severe plaque psoriasis.

Plaque psoriasis is a skin disease that causes red, painful and itchy patches with a silvery white buildup of dead skin cells or scale.

The company's regulatory filing was backed by the results of two phase 3 clinical trials that demonstrated the treatment was better at improving skin clearance than placebo.